Oncologist:全球多中心真实世界探索EGFR-TKIs治疗罕见EGFR突变NSCLC患者的疗效

2022-03-15 网络 网络

该真实世界研究表明,在罕见EGFR突变的NSCLC患者中EGFR-TKI仍是常用治疗手段,对于主要罕见突变和混合突变类型仍可见显著疗效。

表皮生长因子受体酪氨酸激酶抑制剂(EGFR TKIs)是常见敏感EGFR突变阳性((Del19或L858R))非小细胞肺癌(NSCLC)患者的标准治疗;然而,7%-23%的NSCLC肿瘤存在罕见EGFR突变。这些突变是高度异质性的,检测技术的发展有助于在很少或没有临床数据的情况下识别突变。近期,Oncologist杂志上发表了一项国际多中心的回顾性研究(UpSwinG,NCT04179890),旨在评估厄洛替尼,吉非替尼,阿法替尼或奥希替尼一线或二线治疗伴有罕见EGFR突变的NSCLC患者的疗效。

该研究为全球多中心的回顾性研究,终点包括治疗失败时间(TTF)、客观缓解率(ORR)和总生存期(OS)。

总体而言,研究纳入来自9个国家地区的246例患者(中位年龄:69.5岁;亚洲:84%)。从诊断到开始指数治疗的中位时间为0.7个月(四分位数范围[IQR], 0.4-1.7)。总的来说,最常见的目标治疗是阿法替尼。只有7例患者接受了奥希替尼目标治疗。大多数患者(n = 226;91.9%)患者接受EGFR TKI作为一线治疗。只有21例(8.5%)患者在EGFR TKI目标治疗前接受一线化疗。最常见的二线治疗是化疗(60.0%),其次是奥希替尼(15.0%)。共31例患者接受序贯EGFR TKIs作为一线和二线治疗。

根据突变类型将患者分为4组:主要罕见突变(72.8%)、20外显子插入(11.8%)、其他罕见突变(8.5%)和T790M突变(6.9%)。

中位随访19.1个月(IQR, 10.5-31.3)后,接受目标EGFR TKI治疗患者的中位TTF为9.9个月(95% CI, 7.8-11.6),中位OS为24.4个月(95% CI, 20.2-28.2)。接受EGFR TKI作为一线治疗的患者,中位TTF为10.5个月(95% CI, 8.5-12.6), ORR为45.3%。当二线接受EGFR TKIs治疗(n = 20)时,中位TTF为5.8个月(IQR, 2.6-12.8)。20例患者接受一线化疗,中位TTF为6.6个月(95% CI, 4.4-7.9), ORR为41.2%,DOR为4.0个月(IQR, 3.0-7.0)。第一代EGFR TKIs和阿法替尼治疗患者的中位TTF分别为8.8个月(95% CI, 6.4-10.7)和11.3个月(95% CI, 8.5-14.9)。中位OS分别为24.2个月(95% CI, 16.8-31.3)和24.5个月(95% CI, 20.8-27.4)。

阿法替尼治疗时, T790M组中位TTF为5.7个月,主要罕见突变组中位TTF为14.3个月,其中30.4%存在T790M或20外显子插入突变。主要罕见突变组患者的中位OS为2年。第一代EGFR TKIs治疗时, T790M组中位TTF为2.1个月,混合突变组中位TTF为12.4个月,其中21.9%存在T790M或20外显子插入突变。T790M组的中位OS为14.2个月,混合突变组为31.3个月。

接受目标EGFR TKI治疗患者ORR为43.4%,中位缓解持续时间为10.0个月(IQR, 5.0- 16.0)。阿法替尼的ORR为43.8%(中位缓解时间:12.0个月),第一代EGFR TKIs的ORR为44.1%(中位缓解时间:6.0个月)。

综上,该真实世界研究表明,在罕见EGFR突变的NSCLC患者中EGFR-TKI仍是常用治疗手段,对于主要罕见突变和混合突变类型仍可见显著疗效。

 

原始出处:

Popat S, Hsia TC, Hung JY, Jung HA, Shih JY, Park CK, Lee SH, Okamoto T, Ahn HK, Lee YC, Sato Y, Lee SS, Mascaux C, Daoud H, Märten A, Miura S. Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG). Oncologist. 2022 Mar 11:oyac022. doi: 10.1093/oncolo/oyac022. Epub ahead of print. PMID: 35274704.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1940484, encodeId=9d9b19404840e, content=<a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6573, encryptionId=7ed165e3b6, topicName=EGFR-TKIs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Jul 23 05:05:27 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904123, encodeId=ff331904123a1, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed May 25 22:05:27 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069069, encodeId=6915206906992, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jul 16 16:05:27 CST 2022, time=2022-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866545, encodeId=f2be1866545fc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Sep 27 00:05:27 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795748, encodeId=9a2c1e95748c0, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17504, encryptionId=2f311e504f6, topicName=TKIs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37d0457, createdName=yhj-time, createdTime=Tue May 24 20:05:27 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295384, encodeId=16f8129538472, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383105, encodeId=fae81383105b4, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6572, encryptionId=0c8265e2b3, topicName=EGFR-TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384254, encodeId=387f13842545c, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17503, encryptionId=14bb1e503a0, topicName=TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410925, encodeId=d1451410925ea, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455198, encodeId=f2d51455198af, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=)]
    2022-07-23 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1940484, encodeId=9d9b19404840e, content=<a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6573, encryptionId=7ed165e3b6, topicName=EGFR-TKIs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Jul 23 05:05:27 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904123, encodeId=ff331904123a1, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed May 25 22:05:27 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069069, encodeId=6915206906992, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jul 16 16:05:27 CST 2022, time=2022-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866545, encodeId=f2be1866545fc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Sep 27 00:05:27 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795748, encodeId=9a2c1e95748c0, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17504, encryptionId=2f311e504f6, topicName=TKIs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37d0457, createdName=yhj-time, createdTime=Tue May 24 20:05:27 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295384, encodeId=16f8129538472, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383105, encodeId=fae81383105b4, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6572, encryptionId=0c8265e2b3, topicName=EGFR-TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384254, encodeId=387f13842545c, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17503, encryptionId=14bb1e503a0, topicName=TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410925, encodeId=d1451410925ea, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455198, encodeId=f2d51455198af, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1940484, encodeId=9d9b19404840e, content=<a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6573, encryptionId=7ed165e3b6, topicName=EGFR-TKIs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Jul 23 05:05:27 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904123, encodeId=ff331904123a1, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed May 25 22:05:27 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069069, encodeId=6915206906992, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jul 16 16:05:27 CST 2022, time=2022-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866545, encodeId=f2be1866545fc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Sep 27 00:05:27 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795748, encodeId=9a2c1e95748c0, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17504, encryptionId=2f311e504f6, topicName=TKIs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37d0457, createdName=yhj-time, createdTime=Tue May 24 20:05:27 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295384, encodeId=16f8129538472, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383105, encodeId=fae81383105b4, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6572, encryptionId=0c8265e2b3, topicName=EGFR-TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384254, encodeId=387f13842545c, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17503, encryptionId=14bb1e503a0, topicName=TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410925, encodeId=d1451410925ea, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455198, encodeId=f2d51455198af, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=)]
    2022-07-16 jklm09
  4. [GetPortalCommentsPageByObjectIdResponse(id=1940484, encodeId=9d9b19404840e, content=<a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6573, encryptionId=7ed165e3b6, topicName=EGFR-TKIs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Jul 23 05:05:27 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904123, encodeId=ff331904123a1, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed May 25 22:05:27 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069069, encodeId=6915206906992, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jul 16 16:05:27 CST 2022, time=2022-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866545, encodeId=f2be1866545fc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Sep 27 00:05:27 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795748, encodeId=9a2c1e95748c0, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17504, encryptionId=2f311e504f6, topicName=TKIs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37d0457, createdName=yhj-time, createdTime=Tue May 24 20:05:27 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295384, encodeId=16f8129538472, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383105, encodeId=fae81383105b4, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6572, encryptionId=0c8265e2b3, topicName=EGFR-TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384254, encodeId=387f13842545c, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17503, encryptionId=14bb1e503a0, topicName=TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410925, encodeId=d1451410925ea, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455198, encodeId=f2d51455198af, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=)]
    2022-09-27 minlingfeng
  5. [GetPortalCommentsPageByObjectIdResponse(id=1940484, encodeId=9d9b19404840e, content=<a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6573, encryptionId=7ed165e3b6, topicName=EGFR-TKIs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Jul 23 05:05:27 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904123, encodeId=ff331904123a1, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed May 25 22:05:27 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069069, encodeId=6915206906992, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jul 16 16:05:27 CST 2022, time=2022-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866545, encodeId=f2be1866545fc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Sep 27 00:05:27 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795748, encodeId=9a2c1e95748c0, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17504, encryptionId=2f311e504f6, topicName=TKIs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37d0457, createdName=yhj-time, createdTime=Tue May 24 20:05:27 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295384, encodeId=16f8129538472, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383105, encodeId=fae81383105b4, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6572, encryptionId=0c8265e2b3, topicName=EGFR-TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384254, encodeId=387f13842545c, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17503, encryptionId=14bb1e503a0, topicName=TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410925, encodeId=d1451410925ea, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455198, encodeId=f2d51455198af, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=)]
    2022-05-24 yhj-time
  6. [GetPortalCommentsPageByObjectIdResponse(id=1940484, encodeId=9d9b19404840e, content=<a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6573, encryptionId=7ed165e3b6, topicName=EGFR-TKIs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Jul 23 05:05:27 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904123, encodeId=ff331904123a1, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed May 25 22:05:27 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069069, encodeId=6915206906992, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jul 16 16:05:27 CST 2022, time=2022-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866545, encodeId=f2be1866545fc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Sep 27 00:05:27 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795748, encodeId=9a2c1e95748c0, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17504, encryptionId=2f311e504f6, topicName=TKIs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37d0457, createdName=yhj-time, createdTime=Tue May 24 20:05:27 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295384, encodeId=16f8129538472, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383105, encodeId=fae81383105b4, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6572, encryptionId=0c8265e2b3, topicName=EGFR-TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384254, encodeId=387f13842545c, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17503, encryptionId=14bb1e503a0, topicName=TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410925, encodeId=d1451410925ea, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455198, encodeId=f2d51455198af, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1940484, encodeId=9d9b19404840e, content=<a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6573, encryptionId=7ed165e3b6, topicName=EGFR-TKIs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Jul 23 05:05:27 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904123, encodeId=ff331904123a1, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed May 25 22:05:27 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069069, encodeId=6915206906992, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jul 16 16:05:27 CST 2022, time=2022-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866545, encodeId=f2be1866545fc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Sep 27 00:05:27 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795748, encodeId=9a2c1e95748c0, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17504, encryptionId=2f311e504f6, topicName=TKIs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37d0457, createdName=yhj-time, createdTime=Tue May 24 20:05:27 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295384, encodeId=16f8129538472, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383105, encodeId=fae81383105b4, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6572, encryptionId=0c8265e2b3, topicName=EGFR-TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384254, encodeId=387f13842545c, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17503, encryptionId=14bb1e503a0, topicName=TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410925, encodeId=d1451410925ea, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455198, encodeId=f2d51455198af, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1940484, encodeId=9d9b19404840e, content=<a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6573, encryptionId=7ed165e3b6, topicName=EGFR-TKIs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Jul 23 05:05:27 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904123, encodeId=ff331904123a1, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed May 25 22:05:27 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069069, encodeId=6915206906992, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jul 16 16:05:27 CST 2022, time=2022-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866545, encodeId=f2be1866545fc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Sep 27 00:05:27 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795748, encodeId=9a2c1e95748c0, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17504, encryptionId=2f311e504f6, topicName=TKIs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37d0457, createdName=yhj-time, createdTime=Tue May 24 20:05:27 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295384, encodeId=16f8129538472, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383105, encodeId=fae81383105b4, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6572, encryptionId=0c8265e2b3, topicName=EGFR-TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384254, encodeId=387f13842545c, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17503, encryptionId=14bb1e503a0, topicName=TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410925, encodeId=d1451410925ea, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455198, encodeId=f2d51455198af, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=)]
    2022-03-16 lsj628
  9. [GetPortalCommentsPageByObjectIdResponse(id=1940484, encodeId=9d9b19404840e, content=<a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6573, encryptionId=7ed165e3b6, topicName=EGFR-TKIs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Jul 23 05:05:27 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904123, encodeId=ff331904123a1, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed May 25 22:05:27 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069069, encodeId=6915206906992, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jul 16 16:05:27 CST 2022, time=2022-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866545, encodeId=f2be1866545fc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Sep 27 00:05:27 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795748, encodeId=9a2c1e95748c0, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17504, encryptionId=2f311e504f6, topicName=TKIs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37d0457, createdName=yhj-time, createdTime=Tue May 24 20:05:27 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295384, encodeId=16f8129538472, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383105, encodeId=fae81383105b4, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6572, encryptionId=0c8265e2b3, topicName=EGFR-TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384254, encodeId=387f13842545c, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17503, encryptionId=14bb1e503a0, topicName=TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410925, encodeId=d1451410925ea, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455198, encodeId=f2d51455198af, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1940484, encodeId=9d9b19404840e, content=<a href='/topic/show?id=7ed165e3b6' target=_blank style='color:#2F92EE;'>#EGFR-TKIs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6573, encryptionId=7ed165e3b6, topicName=EGFR-TKIs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Jul 23 05:05:27 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904123, encodeId=ff331904123a1, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed May 25 22:05:27 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069069, encodeId=6915206906992, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jul 16 16:05:27 CST 2022, time=2022-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866545, encodeId=f2be1866545fc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Sep 27 00:05:27 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795748, encodeId=9a2c1e95748c0, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17504, encryptionId=2f311e504f6, topicName=TKIs)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37d0457, createdName=yhj-time, createdTime=Tue May 24 20:05:27 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295384, encodeId=16f8129538472, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383105, encodeId=fae81383105b4, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6572, encryptionId=0c8265e2b3, topicName=EGFR-TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384254, encodeId=387f13842545c, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17503, encryptionId=14bb1e503a0, topicName=TKI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410925, encodeId=d1451410925ea, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455198, encodeId=f2d51455198af, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Wed Mar 16 04:05:27 CST 2022, time=2022-03-16, status=1, ipAttribution=)]
    2022-03-16 july_977

相关资讯

Front Oncol:EGFR突变NSCLC伴有脑膜转移(LM)的特征以及临床预后

研究表明,EGFR突变NSCLC患者诊断为LM后,使用奥希替尼治疗有更好的临床结果。而且LM病灶控制是延长这些患者总体生存结局的最有效策略。

Front Oncol:一线TKI联合局部放疗可改善老年NSCLC伴有寡转移患者预后

研究表明,对于老年NSCLC伴有寡转移患者,一线TKI联合局部放疗可改善患者预后,并且毒性可控。

Ther Adv Med Oncol:诊断非小细胞鳞状细胞肺癌的生物标志物大PK!

p40 在诊断非小细胞鳞状细胞肺癌方面具有最佳诊断优势比

European Radiology:确诊肺癌后,是否存在脑转移?影像学有话说

脑转移是非小细胞肺癌(NSCLC)的常见并发症,在病程中的总发生率为40%,在最初诊断时的发生率为15-20%。

BMC Cancer: 基线血清胆碱酯酶(ChE)可作为非小细胞肺癌(NSCLC)患者的独立预后指标

研究表明,基线血清胆碱酯酶(ChE)可作为非小细胞肺癌(NSCLC)患者的独立预后指标。

Front Oncol:真实世界数据探索EGFR 18外显子突变NSCLC患者的治疗策略和预后

研究表明,对于EGFR 18外显子突变NSCLC患者,1代EGFR TKI联合化疗和阿法替尼可能是最佳治疗方式。